Affordable HIV Prevention Drug to Revolutionize Global Access
Dr Reddy's Laboratories and Hetero Labs plan to offer generic versions of Lenacapavir, an effective HIV prevention drug, for $40 annually, starting in 2027. This initiative aims to make the drug accessible to low- and middle-income countries, significantly reducing costs from the U.S. price of $28,000.
In a groundbreaking move, Dr Reddy's Laboratories and Hetero Labs announced their intent to sell affordable generic versions of the HIV prevention drug Lenacapavir by 2027. Valued at approximately $40 annually, this initiative is directed towards enhancing access in low- and middle-income nations.
Lenacapavir, developed by Gilead Sciences under the brand name Yeztugo, demonstrated almost 100% effectiveness in preventing HIV in major trials. Experts believe this cost-effective drug could serve as a pivotal weapon against the persistent HIV epidemic.
The reduced price contrasts sharply with the approximately $28,000 annual U.S. cost, enabled by support from Unitaid, the Clinton Health Access Initiative, and others. These efforts aim to provide equitable healthcare solutions globally.
(With inputs from agencies.)
Google News